Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
|Articles|April 2, 2018
Baxter BioPharm Solutions
BioPharma Solutions, a business unit of Baxter, collaborates with pharmaceutical companies to provide contract manufacturing form/fill/finish for sterile injectables.
Advertisement
BioPharma Solutions, a business unit of Baxter, collaborates with pharmaceutical companies to provide contract manufacturing form/fill/finish for sterile injectables. Our expertise includes oncology products, biologics, ADCs, and vaccines; and we offer a variety of sterile dosage forms, including prefilled syringes, liquid vials, lyophilized vials, cartridges, and cost-saving diluents for reconstitution.
One Baxter Parkway, Deerfield, IL 60015
biopharmasolutions@baxter.com
tel. 224.948.3278
CPhI North America Booth #1445
Advertisement
Related to this article
Today’s BioPharm Brief covers FDA’s final potency assurance guidance for cell and gene therapies, Lonza’s deal to acquire Merck KGaA’s US CDMO business, and Phase 2a data for Tiziana’s intranasal anti-CD3 antibody foralumab in progressive multiple sclerosis.
At AAPS PharmSci 360 2026, University of Iowa PhD candidate Siddhanth Hejmady explains how adding a payload or radiolabel to trastuzumab changes its behavior in bulk solution and at interfaces, and why developability teams should pair DLS with QCM-D.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
In the Phase 2a INFORM-MS trial, Tiziana’s nasal foralumab reduced microglial activation on PET imaging at 50 µg in non-active secondary progressive MS, while the 100-µg dose showed no significant effect.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
4
Teva Licenses US Rights to Samsung Bioepis TNF Inhibitor Biosimilars
5